Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Dose-Response Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma

NCT00128921 is registered in ClinicalTrials.gov with University of Arkansas as lead sponsor.

NCT NCT00128921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00128921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Dose-Response Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
University of Arkansas
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2006
Completion date
February 29, 2008
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma